{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:05:20Z","timestamp":1783998320229,"version":"3.55.0"},"reference-count":14,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJTLD Open"],"accepted":{"date-parts":[[2026,4,20]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>TB is a leading cause of morbidity and mortality, and TB treatment shortening is a focus of TB therapeutic trials. Clofazimine (CFZ) has been proposed as part of a shorter TB regimen but the drug causes skin hyperpigmentation. Patient preferences around shorter regimens with CFZ should be documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      We performed an exploratory, qualitative sub-study using in-depth interviews among purposively selected participants in the CLO-FAST trial (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04311502\">NCT04311502<\/jats:ext-link>\n                      ). Participants were asked about their experience with their assigned treatment regimen and about preferences for treatment. Data were analysed by trained qualitative researchers using the theoretical framework of acceptability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Twenty-three participants from India, Malawi, and Zimbabwe were selected from 89 participants randomised to two study arms in the parent trial. Most participants expressed preference for shorter regimen even if it led to skin hyperpigmentation. Preferences for a longer regimen may have been influenced by anticipated concerns around inadvertent disclosure and by a belief that longer regimens were more potent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Preference assessment can be successfully built into therapeutic TB trials. Most participants preferred shorter treatment but concerns about potency and skin discolouration were expressed. Additional work is needed to describe therapeutic preferences among people with TB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5588\/ijtldopen.26.0179","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:34:51Z","timestamp":1783996491000},"page":"466-470","source":"Crossref","is-referenced-by-count":0,"title":["An exploratory, qualitative study of treatment preferences among participants in a TB therapeutic trial"],"prefix":"10.5588","volume":"3","author":[{"given":"F.","family":"Mugodhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kanyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Makiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Potani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.K.","family":"Scarsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Furin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the A5362\/CLO-FAST study team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026071319344535000_3.7.466.1","unstructured":"World Health Organization . Global Tuberculosis Report 2024. Geneva: WHO, 2024."},{"issue":"6","key":"2026071319344535000_3.7.466.2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S2213-2600(21)00161-2","article-title":"Challenges and opportunities to end tuberculosis in the COVID-19 era","volume":"9","author":"Wingfield","year":"2021","journal-title":"Lancet Resp Med"},{"issue":"7","key":"2026071319344535000_3.7.466.3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S1473-3099(24)00007-0","article-title":"Global, regional, and national ag-specific progress towards the 2020 milestones of the WHO endTB strategy: a systematic analysis for the Global Burden of Diseases Study 2021","volume":"24","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2026071319344535000_3.7.466.4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S2213-2600(23)00090-5","article-title":"Advances in tuberculosis control in the past decade","volume":"11","author":"Naidoo","year":"2023","journal-title":"Lancet Resp Med"},{"issue":"7","key":"2026071319344535000_3.7.466.5","doi-asserted-by":"crossref","first-page":"e00636","DOI":"10.1128\/AAC.00636-18","article-title":"Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis","volume":"62","author":"Ammerman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071319344535000_3.7.466.6","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0144"},{"key":"2026071319344535000_3.7.466.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70228-6"},{"issue":"4","key":"2026071319344535000_3.7.466.8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/tmi.13977","article-title":"Clofazimine-induced cutaneous hyperpigmentation as a source of stigma in the treatment of leprosy: a cross-sectional study","volume":"29","author":"Noguiera","year":"2024","journal-title":"Trop Med Int Health"},{"key":"2026071319344535000_3.7.466.9","doi-asserted-by":"crossref","unstructured":"Corbin J , Strauss A . Basics of qualitative research: techniques and procedures for developing grounded theory. London, United Kingdom: Sage, 2008.","DOI":"10.4135\/9781452230153"},{"issue":"1","key":"2026071319344535000_3.7.466.10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1473-3099(25)00436-0","article-title":"A 3-month clofazimine\u2013rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial","volume":"26","author":"Metcalfe","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"2026071319344535000_3.7.466.11","doi-asserted-by":"crossref","first-page":"e0001267","DOI":"10.1371\/journal.pgph.0001267","article-title":"Toward a conceptual framework of the acceptability of tuberculosis treatment in children using a theory generative approach","volume":"2","author":"Wademan","year":"2022","journal-title":"PLoS Global Public Health"},{"issue":"9","key":"2026071319344535000_3.7.466.12","doi-asserted-by":"crossref","first-page":"e0273734","DOI":"10.1371\/journal.pone.0273734","article-title":"Anticipated stigma and associated factors among chronic illness patients in Amhara Region Referral Hospitals, Ethiopia: a multicenter cross-sectional study","volume":"17","author":"Salih","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"2026071319344535000_3.7.466.13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5588\/ijtldopen.23.0462","article-title":"Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment","volume":"1","author":"Wademan","year":"2024","journal-title":"IJTLD Open"},{"key":"2026071319344535000_3.7.466.14","doi-asserted-by":"crossref","first-page":"1100488","DOI":"10.3389\/fphar.2023.1100488","article-title":"Clofazimine for the treatment of tuberculosis","volume":"14","author":"Stadler","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["IJTLD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5588\/ijtldopen.26.0179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:34:53Z","timestamp":1783996493000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.theunion.org\/lookup\/doi\/10.5588\/ijtldopen.26.0179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.5588\/ijtldopen.26.0179"],"URL":"https:\/\/doi.org\/10.5588\/ijtldopen.26.0179","relation":{},"ISSN":["3005-7590"],"issn-type":[{"value":"3005-7590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}